Ground-breaking imaging for drug development is at the heart of what we do. Equally important is our extensive expertise in drug development and disease biology. This important mix of capabilities allows us to discuss and advise on study-design and to deliver clinical studies and imaging analysis addressing relevant biology.
Our solutions deliver vital insights that few others can offer – allowing our partners to make the right investment decisions for clinical programs. In close partnership with both major pharmaceutical corporations and biotechs, we create solutions delivered as groundbreaking, complex mechanistic studies as well as large-scale multi-centre imaging studies. Always with precision, specificity and an uncompromising quality.
Today, our focus is on drug development in cardiorenal and metabolic conditions, including NASH* and CKD**, and oncology/immune-oncology. New disease areas will be added in the years to come – especially where imaging methodologies could provide information critical to decision making.
We support our partners through-out study design, delivery and decision support. Our toolbox includes over 50 different imaging methods. Together, Antaros experts have, as authors and co-authors, more than 700 peer-reviewed publications looking at method development, interventional studies and prevalence/cross-sectional studies.
*NASH= Non-Alcoholic SteatoHepatitis
**CKD=Chronic Kidney Disease